Now showing items 1-2 of 2
Phase 2 study of a high dose of 186RE-HEDP for bone pain palliation in patients with widespread skeletal metastases
186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European ...
A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment
The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcinoma (DTC) patients who had received iodine-131 (131I) treatment, and to evaluate hospital discharge planning in relation ...